Alnylam Pharmaceuticals Supports Greater Boston & Norton Communities with its 2nd Annual “Helping Hands” Community Servic...
June 23 2016 - 3:30PM
Business Wire
– Alnylam Community Gives Back in the
Communities it Serves at Ten Local Non-Profit Organizations –
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, today announced that over 400 of its
employees participated in a company-wide community service day
today to benefit ten local non-profit organizations including:
Boston Nature Center, Cradles to Crayons, Emerald Necklace
Conservancy, Friends of Alewife, Habitat Education Center, IMEC
America, Cupboard of Kindness, Norton Conservation Land, West End
House Boys and Girls Club and Windrush Farms.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160623006302/en/
Alnylam Pharmaceuticals Supports Greater
Boston and Norton Communities with its 2nd Annual “Helping Hands”
Community Service Day (Photo: Business Wire)
“One of Alnylam’s Core Values is our ‘Commitment to People’ both
inside and outside the walls of our company,” said John Maraganore,
Ph.D., Chief Executive Officer at Alnylam. “Our ‘Helping Hands’
Community Service Day is a time in which our employee community can
pause and focus on giving back to the communities that we serve and
to the causes our employees personally connect with. We are
thankful to the ten non-profits who have allowed us to share in
their missions.”
As part of its “Commitment to People” and leadership in local
communities, the Company has set aside dedicated time to its second
annual company-wide “Helping Hands” Community Service Day. Last
year, 280 Alnylam employees participated across six sites around
Greater Boston, Cambridge, and the United Kingdom. This year,
Alnylam had an even larger impact, with over 400 employees
participating and dedicating 2,000 hours to give back to the
community. Additionally, this year’s effort expanded Alnylam’s
geographic footprint to include a number of new non-profits in the
Cambridge and Greater Boston area, including in Norton, Mass., the
site of the Company’s future manufacturing facility.
About Alnylam PharmaceuticalsAlnylam is a
biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is leading the translation
of RNAi as a new class of innovative medicines. Alnylam's pipeline
of investigational RNAi therapeutics is focused in 3 Strategic
Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline
of RNAi therapeutics for the treatment of rare diseases;
Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics
toward genetically validated, liver-expressed disease targets for
unmet needs in cardiovascular and metabolic diseases; and Hepatic
Infectious Disease, with a pipeline of RNAi therapeutics that
address the major global health challenges of hepatic infectious
diseases. In early 2015, Alnylam launched its "Alnylam 2020"
guidance for the advancement and commercialization of RNAi
therapeutics as a whole new class of innovative medicines.
Specifically, by the end of 2020, Alnylam expects to achieve a
company profile with 3 marketed products, 10 RNAi therapeutic
clinical programs – including 4 in late stages of development –
across its 3 STArs. The company's demonstrated commitment to RNAi
therapeutics has enabled it to form major alliances with leading
companies including Ionis, Novartis, Roche, Takeda, Merck,
Monsanto, The Medicines Company, and Sanofi Genzyme. In addition,
Alnylam holds an equity position in Regulus Therapeutics Inc., a
company focused on discovery, development, and commercialization of
microRNA therapeutics. Alnylam scientists and collaborators have
published their research on RNAi therapeutics in over 200
peer-reviewed papers, including many in the world's top scientific
journals such as Nature, Nature Medicine, Nature Biotechnology,
Cell, New England Journal of Medicine, and The Lancet. Founded in
2002, Alnylam maintains headquarters in Cambridge, Massachusetts.
For more information about Alnylam's pipeline of investigational
RNAi therapeutics, please visit www.alnylam.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160623006302/en/
Alnylam Pharmaceuticals, Inc.Investors and MediaChristine
Regan Lindenboom, 617-682-4340orInvestorsJosh Brodsky,
617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2024 to May 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From May 2023 to May 2024